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Weight loss interventions may be considered as an option for a 
lifestyle treatment in urinary incontinence in adults. 
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KEY POINTS  
• There were signs that weight loss management may be effective in improve symptoms in UI, 
specific urinary incontinence quality-of-life and prevalence of weekly UI.   
• There is limited evidence on the effectiveness of caffeine reduction, or a soy-rich diet and no 
evidence found for physical activity, sweetened fizzy drinks or diet drinks, smoking cessation, 
constipation, and alcohol on urinary incontinence in adults 
• Further high-quality random controlled trials are required to assess the effectiveness of 
lifestyle interventions for adults with UI. 
• Future research for the effectiveness of lifestyle interventions for adults with urinary 
incontinence should ensure to use specific urinary incontinence outcome sets.  
 
Introduction 
Urinary incontinence (UI) (involuntary or abnormal urine loss) is a common condition affecting an 
estimated 423 million individuals around the world (Irwin et al. 2011). Its prevalence varies, ranging 
from between 5-15.2% in Asian, 1.8-30.5% in European and 1.7-36.4% in US  populations (Milsom et 
al. 2014). This condition can have a significant clinical (Yang et al. 2018), psychological (Farage et al. 
2008; Sims et al. 2011), and financial impact (Thom et al. 2010) on an individual’s life.  The risk of 
developing UI is associated with several non-modifiable modifiable risk factors of age (Milsom and 
Gyhagen 2019), gender (Nitti 2001) and family history (von Gontard et al. 2011) and modifiable risk 
factors of weight (Aune et al. 2019), smoking (Kawahara et al. 2020), diet (Maserejian et al. 2010) and 
caffeine intake (Gleason et al. 2013). Despite the association with such modifiable risk factors, there 
is limited evidence supporting interventions which aim to affect their influence (Imamura et al. 2015). 
This Cochrane systematic review aimed to evaluate the effectiveness of a range of lifestyle focused 
interventions which are commonly used in the management of UI.  
Aims of commentary: This commentary critically appraises the methods used in the Cochrane 
systematic review and consider its importance of the findings for clinical practice. 
 
Methods 
This Cochrane systematic review undertook a comprehensive search of the Cochrane Central Register 
of Controlled Trials, and MEDLINE using a previously validated search procedure from date of 
inception to 3 July 2013. Additional handsearching, citation list and clinical trial registry searches were 
performed. There were no language restrictions placed on the search procedure. Only randomised 
control trials (RCTs) or quasi-randomised trials which compared lifestyle interventions to no active 
control treatment for adults with UI were included. A post hoc decision was made to include studies 
where all participants did not have to have UI on entering the trial. 
A robust study selection, data extraction and assessment of risk of bias (Cochrane assessment of bias 
criteria) was undertaken independently by two reviewers with disagreements being resolved by 
discussion (Higgins 2020). A summary statement of quality for each outcome was produced using the 
GRADE criteria (Guyatt et al. 2008). A meta-analysis was undertaken using a fixed effect model, 
estimating relative risks for dichotomous outcomes and Mantel-Haenszel weighted mean differences 
for continuous outcomes. A range of subgroup analyses were planned but were not undertaken due 
to a lack of data. A narrative synthesis was undertaken for adverse events due to a similar lack of 
numerical data. 
Findings 
Eleven studies were included of mixed design of which six were RCTs, four were crossover trials and 
one was a quasi-randomised trial. Out of the seven criteria for assessment of bias only two studies 
had a low risk of bias on four out of the seven criteria, namely randomisation, allocation concealment 
and blinding of outcome assessment and incomplete outcome data.  The three main areas of concern 
were a lack of blinding of participants, appropriate allocation concealment and selective reporting bias 
due to limited protocols being identified for the included studies. Out of the 11 studies included, seven 
studies had mixed UI and non-diagnosed UI populations, ranging from 27% to 83% UI populations.  
The review found that weight loss interventions resulted in adults with UI being statistically and 
clinically significantly more likely to report improvement in symptoms, incontinence impact 
questionnaire, cure rates by symptom quantification (low quality evidence: 1 studies) and 
improvement rates by symptom quantification compared to non-active controls (low quality evidence: 
2 studies). On visual inspection of the forest plot for risk ratio of quantification of symptoms, there is 
some evidence that weight loss intervention becomes less effective over time (18 months follow-up), 
with the main effect moving towards the line of no effect. There was also a statistically and clinically 
significant reduction in prevalence of weekly UI (very low-quality evidence: 1 study). One study 
reported that the intervention had “few side effects”.  
One study demonstrated a statistical and clinically significant reduction in prevalence of weekly UI for 
lifestyle weight loss compared to the pharmacological intervention of metformin.  For the intervention 
of restricting fluid intake there was mixed findings. There was one study out of three which 
demonstrated a statistically significant reduction in UI within a week (very low quality of evidence) 
and one study demonstrated improvement in quality of life compared to baseline measurements (very 
low quality of evidence). Two studies reported adverse events which included concentrated urine, 
constipation, headache, and thirst. Evidence on the effect’s caffeine reduction and a soy-rich diet was 
limited and of low quality, preventing any conclusions. 
Commentary 
Although the systematic review appeared robust when assessed using the Amstar2 critical appraisal 
tool (only considered inadequate on justification of study type selection), it had an important 
limitation that rendered it of “low confidence” (Shea et al. 2017). A post-hoc decision to include 
data from trials where not all participants were incontinent when they entered the trial, reduced the 
relevance of its findings to adults with UI. It is unclear as to when this decision was made, which may 
have led to important studies being missed during study selection. This limitation is further 
compounded by the limited and low quality evidence identified by the systematic review. 
Consequently, these findings should be viewed with caution. 
Based on this limited evidence there are signs that weight loss interventions may be considered as an 
option for a lifestyle treatment due to some signs of effectiveness to improve symptoms in UI, 
prevalence of weekly UI and there being limited adverse events. Previous systematic reviews have 
shown a positive association with increased BMI and risk of UI (Aune et al. 2019; Lamerton et al. 2018). 
Furthermore, previous reviews have shown that weight management interventions can be cost-
effective (Finkelstein and Verghese 2019; Forster et al. 2011; Loveman et al. 2011). However, the 
Cochrane systematic review found there was some evidence to suggest that the intervention of weight 
loss maybe less effective over time. This should be considered when recommending this intervention 
as regular assessments may be required to ensure continuation of effectiveness. 
There was limited evidence to suggest a benefit from reducing fluid intake despite previous reviews 
finding the association between fluid intake and urinary frequency and urgency in men and women 
(Bradley et al. 2017). A range of adverse effects were also identified. As such reduced fluid intake 
interventions should be considered with caution.  
There was limited or inconsistent evidence on the effectiveness of caffeine reduction or a soy-rich diet 
and no evidence found for physical activity, sweetened fizzy drinks or diet drinks, smoking cessation, 
constipation, and alcohol. Even though there are inconsistencies in the evidence base identified in this 
Cochrane review, the current NICE guidelines recommend that caffeine reduction, fluid modification 
and weight loss management should be considered (NICE 2015; 2019). Where these uncertainties still 
exist, there are other important aspects which can be taken into consideration such as sensitivity to 
the intervention, type of UI, patient preference and any caregiver needs (Demaagd and Davenport 
2012; Lobchuk and Rosenberg 2014; Lukacz et al. 2017)  
Further high-quality random controlled trials are required to assess the effectiveness of lifestyle 
interventions for adults with UI.  Priority should be given to weight loss management due to this 
intervention type currently having the strongest evidence of effect. Due to the sparsity of the 
evidence, the areas of physical activity, sweetened fizzy drinks or diet drinks, smoking cessation, 
constipation, and alcohol should be explored. All future RCTs in this area should ensure that there is 
consistency in outcomes used by adopting relevant UI outcome sets for the type of UI (CHORUS 2020). 
Due to the scoping issues of this review and the out-of-date search procedure an update of this 
Cochrane review is required.  
 
CPD REFLECTIVE QUESTIONS 
 
• What was the main limitation of this Cochrane systematic review? 
• What factors should be considered when prescribing lifestyle interventions for adults with 
urinary incontinence? 
• What additional strategies can be put in place if uncertainties lie within the effectiveness of 
an intervention? 
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